Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsStanford researchers engineered a two-part molecule that hijacks a key lymphoma-driving protein and turns it into a trigger for cancer cell death. In mice, the experimental compound wiped out aggressive human lymphoma tumors completely within just 11 days. The approach could eventually extend to other cancers and autoimmune diseases.
Stanford Medicine researchers have developed an experimental molecule called TCIP3 that doesn't just block a cancer-promoting protein — it weaponizes it. The molecule targets BCL6, a protein that normally helps lymphoma cells survive by silencing genes that would trigger cell death. Instead of simply shutting BCL6 down, TCIP3 connects it to other proteins that chemically reprogram it, flipping those same death-related genes into overdrive.
Think of it like the difference between easing off a car's brake versus flooring the accelerator. In mice implanted with aggressive human lymphoma tumors, twice-daily TCIP3 treatment caused tumors to completely disappear within 11 days — with no signs of toxicity or dangerous inflammation. Structural studies also revealed that TCIP3 acts as a "molecular glue," causing the proteins it connects to bond more tightly than expected, amplifying its effect.
Key Takeaways:
Why it matters: This research introduces a fundamentally new strategy for fighting cancer — not by blocking harmful proteins, but by turning them against the very cells that depend on them. If the approach translates to humans, it could open a new class of treatments for lymphoma and beyond.
